Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ways to discover and develop antibodies. As they refined the process to make better antibodies (what is now the NeoAb process), they established a service business to make high-quality antibodies for others.
By 2002 the founders realized a need to bring in business expertise to help grow the company by leveraging its ability to make excellent antibodies. This change in direction is the foundation of what NeoClone is today - a company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostics. As a result of these efforts, we now have over 1000 customers in 30+ countries.
To poise ourselves for future success, we've continued to refine our antibody development abilities. In 2014, we added antibody phage display technology to help us develop the diverse and specific antibody repertoire to certain difficult targets that might be difficult to achieve with hybridoma technology alone. We have developed camelid (VHH) antibody capabilities so we can service the rapidly growing therapeutics market. We have been offering this service since 2015.
Want to know more? Deven McGlenn, NeoClone's CEO, will be happy to help.